Grant: Op. Gr.:Emerging COVID-19 Res. Gaps & Priorities - HIV and SARS-CoV-2
Memorial University of Newfoundland
$286,800.00
Immunogenicity and durability of COVD-19 vaccines in persons living with human immunodeficiency virus
FY 2021-22
Summary
Despite the effectiveness of antiretroviral drug treatment, persons living with HIV (PLWH) can have weakened immune systems that respond poorly to vaccination, compared to the general population. Little is known about how PLWH respond to the novel mRNA or viral vector-based vaccines developed against COVID-19 . As they may be more prone to develop severe infection, it is important to determine how well the vaccines work and how long vaccine-induced immunity lasts in PLWH. If there is a weaker response to the vaccines in PLWH, this would indicate that additional doses and more frequent boosting may be required to provide adequate protection. We will study the responses of approximately 200 PLWH who received matched or unmatched COVID-19 vaccines to find out what factors related to HIV infection affect responsiveness to the vaccination and the need for additional vaccine doses.
Department
Program
Op. Gr.:Emerging COVID-19 Res. Gaps & Priorities - HIV and SARS-CoV-2
Recipient
Location
Newfoundland and Labrador, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
459257
Name
Grant Michael D
Region
Newfoundland and Labrador
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Operating Grant: Emerging COVID-19 Research Gaps & Priorities (July 2021)
Projecttitle
Immunogenicity and durability of COVD-19 vaccines in persons living with human immunodeficiency virus
Programtype2
Operating Grants
Orgnameinp2
Memorial University of Newfoundland
Cihramount2
$286,800
Cihrequipment2
$0
Programname2
Op. Gr.:Emerging COVID-19 Res. Gaps & Priorities - HIV and SARS-CoV-2
Keyworddelim
Adcc; Antibodies; Covid-19 Vaccines; Plwh; T Cells
Abstract
Despite the effectiveness of antiretroviral drug treatment, persons living with HIV (PLWH) can have weakened immune systems that respond poorly to vaccination, compared to the general population. Little is known about how PLWH respond to the novel mRNA or viral vector-based vaccines developed against COVID-19 . As they may be more prone to develop severe infection, it is important to determine how well the vaccines work and how long vaccine-induced immunity lasts in PLWH. If there is a weaker response to the vaccines in PLWH, this would indicate that additional doses and more frequent boosting may be required to provide adequate protection. We will study the responses of approximately 200 PLWH who received matched or unmatched COVID-19 vaccines to find out what factors related to HIV infection affect responsiveness to the vaccination and the need for additional vaccine doses.
Competitiondate
202109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Grant, Michael D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $286,800~ $0~
